Current progress in targeted therapy for colorectal cancer

Jose Ortega, Carlos E. Vigil, Catherine Chodkiewicz*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations

Abstract

Background: Several molecular targeting agents are available and being used in patients with colorectal cancer, and many others are being tested clinically. Methods: The authors review and present the biology and use, including predictive testing, of the agents currently approved for use in colorectal cancer as well as current data on several newer tyrosine kinase inhibitors that are undergoing clinical trials. Results: The angiogenesis inhibitor bevacizumab and the two EGFR inhibitors cetuximab and panitumumab are currently the three targeted agents approved in colorectal cancer. Recent studies show that the combined use of bevacizumab and EGFR inhibitors may lead to increased toxicity and inferior outcome. Much remains to be understood regarding these drugs and other targeted therapies as well as the underlying mechanism of tumor resistance or responsiveness to treatment. Their optimal use and sequencing with other treatment modalities such as surgery need to be further refined. Conclusions: There is a crucial need for identification of predictive markers of response and identification of possible negative interactions between targeted agents so that we can better select patients likely to respond to treatment.

Original languageEnglish (US)
Pages (from-to)7-15
Number of pages9
JournalCancer Control
Volume17
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Current progress in targeted therapy for colorectal cancer'. Together they form a unique fingerprint.

Cite this